Pisgah Labs Inc. Company Profile
We are Pisgah Labs.
Our successes and goals in the industry are grounded in 30 years of experience in quality contract manufacturing, cutting-edge technology and business partnerships that pair smart branding strategy with sound intellectual property. We take great pride in our proven ability to add value through our expertise and skill in creating pharmaceutical technology solutions that aid in safe prescription drug use.
The demanding and fast paced dynamics of today's pharmaceutical market place requires an integrated product development plan-a plan founded on comprehensive intellectual property, a focus on brand promotion, and strict regulatory compliance. With Pisgah labs' commitments to innovative technology, business development and cGMP manufacturing your brand and product concepts become commercial realities.
News from Pisgah Labs Inc.:
Generics and Some Brands May Lose $7 Billion Pain Market as Pisgah Labs Develops Abuse Deterrent Products
PISGAH FOREST, N.C., June 12, 2013 /PRNewswire/ — As controversy surrounds the recent FDA decisions concerning abuse deterrent forms of oxycodone drug products, Pisgah Laboratories, Inc. (www.pisgahlabs.com) achieves another technical milestone which may radically alter the landscape for pain medication regulations. Recently, the FDA ruled that the Abbreviated New Drug Applications (ANDAs) — competitive to Purdue […]
Abuse Deterrent Technology Promises Annual Budget Savings Exceeding $200 Billion
PISGAH FOREST, N.C., March 5, 2013 /PRNewswire/ — Pisgah Laboratories, Inc. has announced the launch of a new website to assist in its abuse deterrent technology licensing efforts. Over the past several years, Pisgah (www.pisgahlabs.com) has elucidated a technical means to address the Nation's drug abuse epidemic as declared by the Center for Disease Control […]
Pisgah Laboratories Receives Patent for Innovative Abuse-Deterrent Technology Targeting Pseudoephedrine and Ephedrine, Common Ingredients for Methamphetamine Production
PISGAH FOREST, N.C., Dec. 20, 2012 /PRNewswire/ — Pisgah Laboratories, Inc. (www.Pisgahlabs.com), an innovative pharmaceutical development company located in Western North Carolina, may have some relief for those who regularly fall victim to the cough, cold and allergy season. Pisgah recently received US Patent 8,334,322 from the United States Patent and Trademark Office (www.uspto.gov) for […]
Abuse Deterrent Medicines Developer Pisgah Laboratories, Inc. Wins Top 5 Technologies Award from CLAAD
Center for Lawful Access and Abuse Deterrence recognizes Pisgah for its efforts to reduce the U.S. drug abuse crisis PISGAH FOREST, N.C., Dec. 7, 2012 /PRNewswire/ — Pisgah Laboratories, Inc., an innovative intellectual property and drug development company located in Western North Carolina, was recently recognized for their technical achievements to reduce the Nation's drug […]
Pisgah Laboratories, Inc. Scores a Triple Play in the World Series Against Prescription Drug Abuse
PISGAH FOREST, N.C., Nov. 12, 2012 /PRNewswire/ — Pisgah Laboratories, Inc. (www.pisgahlabs.com) has recently received three Notices of Allowance for United States Patents related to its abuse deterrent medications platform. Earlier this year, Pisgah obtained US Patent 8,211,905 emanating from work conducted at their facility in Pisgah Forest, NC. The latest Notices represent additional milestones to […]
Scientists Focus Innovations to Reduce Deaths From Prescription Drug Abuse
PISGAH FOREST, N.C., May 31, 2012 — Pisgah Laboratories, Inc. (www.pisgahlabs.com) received Notice of Allowance from the United States Patent and Trademark Office (www.uspto.gov) for its patent application entitled "Opioid Salts and Formulations Exhibiting Anti-Abuse and Anti-Dose Dumping Properties." Pisgah began pursuing a technology platform in 2006 that addresses the nation's drug abuse epidemic and […]
Latest Addition to Patent Portfolio Hammers Prescription Drug Abuse and Creates New Market
PISGAH FOREST, N.C., May 17, 2011 — Responding quickly to the FDA's proclaimed new limits on acetaminophen in prescription painkiller combination products, Pisgah Laboratories, Inc., http://www.pisgahlabs.com, files a patent application on abuse deterrent features for opioid drug products. Filed with the US Patent & Trademark Office (http://www.uspto.gov), this new patent application is the eighteenth filing […]
Abuse Deterrent Hydrocodone / Acetaminophen Leads NDA Pipeline
PISGAH FOREST, N.C., Jan. 19, 2011 — As Pisgah Laboratories, Inc. continues development of its lead abuse deterrent opioid product, it will soon begin scale-up of its patent-pending form of hydrocodone. Pisgah has developed a specialized salt form of hydrocodone which imparts abuse deterrent properties to a dosage product. Pisgah will manufacture its hydrocodone salt […]
Research Study Validates Technology for Abuse Deterrent Prescription Drugs
PISGAH FOREST, N.C., Dec. 8, 2010 — Pisgah Labs announced today the findings from a proof of concept study confirming Pisgah's technology imparts abuse deterrence to commonly abused prescription drugs, particularly narcotics. The controlled study, conducted in dogs, was performed with the un-formulated active ingredient, hydrocodone, as modified according to a host of patent applications […]
Therapeutic Discovery Grant Accelerates Investigational New Drug with Abuse Deterrent Technology
PISGAH FOREST, N.C., Nov. 4, 2010 — Pisgah Labs, Inc. (http://www.pisgahlabs.com), an innovative drug development and active ingredient manufacturer located in Western North Carolina, has received a substantial federal grant. The Qualifying Therapeutic Discovery Project Program (http://www.grants.nih.gov/grants/funding/QTDP_PIM/index.htm) made funding available to promising new technologies ready for pre-clinical or clinical trials, and to support filing of […]
Pisgah Labs' Invention Improves Safety of Thyroid Hormones
PISGAH FOREST, N.C., Aug. 17, 2010 — Today, Pisgah Labs, Inc. (http://www.pisgahlabs.com) received a Notice of Allowance from the United States Patent and Trademark office (http://www.uspto.gov) for an important new technology patent addressing global stability problems of thyroid hormone drugs. According to the FDA (http://www.fda.gov): "Thyroid hormones effect protein, lipid, and carbohydrate metabolism, growth and […]
Pisgah Labs, Inc. Announces Patent Issuance, Readies 11th Application Focused on ADD/ADHD Compositions of Abuse Deterrent Drugs
PISGAH FOREST, N.C., June 30, 2010 — Pisgah Labs, Inc., a drug product development company and an active pharmaceutical ingredient manufacturer, is pleased to announce the May 18, 2010 issuance of US Patent 7,718,649. This patent culminates several years of work and investment by Pisgah Labs, Inc. (http://www.pisgahlabs.com) to demystify the physical states of Imipramine […]
Pisgah Labs Receives Notice of Patent Allowance
PISGAH FOREST, N.C., March 25, 2010 — Pisgah Labs, a drug product development company and an active pharmaceutical ingredient manufacturer (API) located in western North Carolina, has received a patent allowance in a series of patent applications. The US Patent & Trademark Office (USPTO) has notified Pisgah Labs, Inc. (http://www.pisgahlabs.com) that a patent application related […]
Pisgah Labs, Inc. Tackles Prescription Drug Abuse As It Files Eighth Patent
PISGAH FOREST, N.C., Jan. 12, 2010 — According to the Office of National Drug Control Policy (http://www.whitehousedrugpolicy.gov), prescription drug abuse is more prevalent than abuse of cocaine, heroin and methamphetamine. In fact, in the past year, prescription drug abuse ranked second only to marijuana use. In the face of this growing problem, Pisgah Labs, Inc. […]
